Risk of infection in MPN patients in the era of Covid‐19: A prospective multicenter study of 257 patients from the CML‐MPN Quebec Research Group von Simpson‐Poirier, Kevin, Harnois, Michaël, Olney, Harold J., Sirhan, Shireen, Gratton, Michel‐Olivier, Assouline, Sarit, Laneuville, Pierre, Delage, Robert, Mollica, Luigina, Busque, Lambert, Szuber, Natasha

Volltext

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia von Klil‐Drori, Adi J., Yin, Hui, Azoulay, Laurent, Del Corpo, Alexa, Harnois, Michaël, Gratton, Michel‐Olivier, Olney, Harold J., Delage, Robert, Laneuville, Pierre, Mollica, Luigina, Busque, Lambert, Assouline, Sarit E.

Volltext

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors von Watson, Mark, Roulston, Anne, Bélec, Laurent, Billot, Xavier, Marcellus, Richard, Bédard, Dominique, Bernier, Cynthia, Branchaud, Stéphane, Chan, Helen, Dairi, Kenza, Gilbert, Karine, Goulet, Daniel, Gratton, Michel-Olivier, Isakau, Henady, Jang, Anne, Khadir, Abdelkrim, Koch, Elizabeth, Lavoie, Manon, Lawless, Michael, Nguyen, Mai, Paquette, Denis, Turcotte, Émilie, Berger, Alvin, Mitchell, Matthew, Shore, Gordon C., Beauparlant, Pierre

Volltext

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study von Klil-Drori, Adi J, Yin, Hui, Azoulay, Laurent, Harnois, Michaël, Gratton, Michel-Olivier, Busque, Lambert, Assouline, Sarit E

Volltext

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response von Klil-Drori, Adi J, Yin, Hui, Azoulay, Laurent, Harnois, Michaël, Gratton, Michel-Olivier, Del Corpo, Alexa, Olney, Harold J, Delage, Robert, Laneuville, Pierre, Mollica, Luigina, Busque, Lambert, Assouline, Sarit E

Volltext

Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777 von Beauparlant, Pierre, Bédard, Dominique, Bernier, Cynthia, Chan, Helen, Gilbert, Karine, Goulet, Daniel, Gratton, Michel-Olivier, Lavoie, Manon, Roulston, Anne, Turcotte, Émilie, Watson, Mark

Volltext

Hes6 Promotes Cortical Neurogenesis and Inhibits Hes1 Transcription Repression Activity by Multiple Mechanisms von Gratton, Michel-Olivier, Torban, Elena, Jasmin, Stephanie Belanger, Theriault, Francesca M., German, Michael S., Stifani, Stefano

Volltext

HES6 Acts as a Transcriptional Repressor in Myoblasts and Can Induce the Myogenic Differentiation Program von Gao, Xiangming, Chandra, Tanya, Gratton, Michel-Olivier, Quélo, Isabelle, Josée Prud'homme, Stifani, Stefano, St-Arnaud, René

Volltext

Risk of infection in MPN patients in the era of C ovid‐ 19 : A prospective multicenter study of 257 patients from the CML‐MPN Q uebec R esearch G roup von Simpson‐Poirier, Kevin, Harnois, Michaël, Olney, Harold J., Sirhan, Shireen, Gratton, Michel‐Olivier, Assouline, Sarit, Laneuville, Pierre, Delage, Robert, Mollica, Luigina, Busque, Lambert, Szuber, Natasha

Volltext

Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study von Klil-Drori, Adi J., Yin, Hui, Azoulay, Laurent, Del Corpo, Alexa, Harnois, Michael, Gratton, Michel-Olivier, Busque, Lambert, Assouline, Sarit

Volltext

Patient-reported outcomes (PROs) programs for monitoring symptoms among patients treated with immunotherapy: A scoping review von Lambert, Sylvie D, Soldera, Sara, Kazdan, Jordana, Frati, Francesca, Slominska, Anita, Boutin, Melina, Samouelian, Vanessa, Letendre, Caroline, Bilodeau, Karine, Howell, Doris, Breton, Karine Le, Gratton, Michel-Olivier

Volltext

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia von Klil-Drori, Adi J., Azoulay, Laurent, Yin, Hui, Del Corpo, Alexa, Harnois, Michaël, Gratton, Michel-Olivier, Chamakhi, Ines, Delage, Robert, Mollica, Luigina, Laneuville, Pierre, Olney, Harold J., Busque, Lambert, Assouline, Sarit E.

Volltext

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia von Klil-Drori, Adi J, Azoulay, Laurent, Yin, Hui, Gratton, Michel-Olivier, Harnois, Michaël, Chamakhi, Ines, Delage, Robert, Laneuville, Pierre, Mollica, Luigina, Olney, Harold J., Busque, Lambert, Assouline, Sarit E.

Volltext